CSF3 and acute myeloid leukemia: A recent cohort study evaluated the efficacy of DEC, LDAC, aclarubicin, and granulocyte colony-stimulating factor (G-CSF) [DCAG regimen] versus standard chemotherapy in TP53mut AML patients [37], based on the previous encouraging results of a multicenter phase 2 trial which reported 82.4% ORR and 64.7% CR rates relating to the DCAG regimen in elderly AML patients [45].